AbbVie Deal History & Licensing Activity
AbbVie is a large pharma headquartered in US. Over the past three years, AbbVie has been involved in 62 licensing and acquisition transactions, with a primary focus on Small Molecules (16 deals). The company currently has 50 active clinical trials, primarily in Oncology.
Deals (12mo)
15
Active Trials
50
Top Modality
Small Molecules
Focus Area
Oncology
AbbVie Recent Deal Activity
Licensing, acquisition, and partnership transactions involving AbbVie in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| KST-6051 | Kestrel Therapeutics | Small Molecules | Unknown | acquisition | Apr 2026 |
| HSK55718 and HSK51155 | Haisco Pharmaceutical Group | Small Molecules | Preclinical | license | Apr 2026 |
| reproxalap | Aldeyra Therapeutics | Small Molecules | Phase 3 | option | Apr 2026 |
AbbVie Pipeline Focus
Therapeutic areas and modalities where AbbVie is most active based on deal history and clinical trial data.
Therapeutic Areas
AbbVie Strategic Signals
Key indicators of AbbVie's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
AbbVie Clinical Pipeline
AbbVie has 50 active clinical trials across 5 development phases.
2
Phase 4
8
Unknown
15
Phase 1
21
Phase 2
4
Phase 3
See How Your Asset Matches AbbVie's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Oncology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Ophthalmology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for ophthalmology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
About AbbVie Licensing & Deal Activity
AbbVie is a large pharma company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 62 deals over the past three years, AbbVie ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for AbbVie include Oncology (34 deals and trials), Ophthalmology (11 deals and trials), Hematological Malignancies (9 deals and trials), and Dermatology (8 deals and trials). In terms of modality, AbbVie has shown particular interest in small molecules, antibodies, peptides.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for AbbVie and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against AbbVie's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.